Related Experiment Video
Updated: May 27, 2025

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Targeting TUBB2B inhibits triple-negative breast cancer growth and brain-metastatic colonization
Qingling He1,2, Jianyang Hu1,2, Fung-Yin Ngo3
1Department of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.
Background:
The triple-negative subtype of breast cancer is particularly challenging to treat due to its aggressiveness with a high risk of brain metastasis, and the lack of effective targeted therapies. Tubulin beta 2B class IIb (TUBB2B), a β-tubulin isoform regulating axon guidance during embryonic development, was found to be overexpressed in various types of cancers including triple-negative breast cancer (TNBC). However, its functional roles in breast cancer or metastasis remain unclear.
Methods:
To identify TUBB2B as a novel molecular target in TNBC, we performed bioinformatics analysis to assess the association of TUBB2B expression and survival of patients. RNAscope in situ hybridization was used to examine TUBB2B expression in clinical breast tumor samples. The effect of TUBB2B knockdown on TNBC growth and brain metastasis colonization was evaluated by in vitro and in vivo assays. Mass spectrometry (MS) and biochemical experiments were performed to explore the underlying mechanisms. Preclinical efficacy of targeting TUBB2B was determined in xenograft studies using the siRNA-gold nanoparticle (siRNA-AuNP) approach.
Results:
TUBB2B, but not other β-tubulin isoforms, is frequently overexpressed in TNBC primary tumors as well as brain metastases. We also find that upregulation of TUBB2B is associated with poor prognosis in breast cancer patients. Silencing TUBB2B induces tumor cell death and inhibits the outgrowth of brain metastasis. Mechanistically, we identify eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) as a novel interacting partner of TUBB2B, revealing a previously unexplored role of TUBB2B in translational regulation. In line with its neural-related functions, TUBB2B overexpression in TNBC cells activates astrocytes, which in turn upregulate TUBB2B in tumor cells. These findings suggest a feed-forward interaction between TUBB2B in TNBC cells and astrocytes that promotes brain metastatic colonization. Furthermore, we demonstrate the potent inhibition of TNBC xenograft growth as well as brain metastatic colonization using TUBB2B siRNA-AuNP treatment, indicating potential clinical applications of targeting TUBB2B for TNBC.
Conclusions:
TUBB2B is a novel TNBC gene that plays a key role in promoting tumor cell survival and brain metastatic colonization, and can be targeted by siRNA-AuNPs as a treatment strategy.
Insights
Triple-negative breast cancer (TNBC) overexpresses TUBB2B, promoting tumor survival and brain metastasis. Targeting TUBB2B with siRNA-gold nanoparticles offers a promising therapeutic strategy for TNBC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) presents significant treatment challenges due to its aggressive nature and high propensity for brain metastasis.
- The β-tubulin isoform TUBB2B is overexpressed in TNBC, but its specific role in cancer progression and metastasis is not well understood.
Purpose of the Study:
- To investigate TUBB2B as a potential therapeutic target in TNBC.
- To elucidate the mechanisms by which TUBB2B contributes to TNBC growth and brain metastasis.
Main Methods:
- Bioinformatics analysis of patient data to correlate TUBB2B expression with survival.
- RNAscope in situ hybridization to assess TUBB2B expression in clinical samples.
- In vitro and in vivo assays to evaluate the effects of TUBB2B knockdown on TNBC.
- Mass spectrometry and biochemical experiments to identify interacting partners and mechanisms.
- Preclinical xenograft studies using siRNA-gold nanoparticles (siRNA-AuNP) to test therapeutic efficacy.
Main Results:
- TUBB2B is frequently overexpressed in TNBC tumors and brain metastases, correlating with poor patient prognosis.
- TUBB2B knockdown inhibits TNBC cell survival and brain metastasis.
- TUBB2B interacts with eEF1A1, suggesting a role in translational regulation.
- A feed-forward loop involving TUBB2B in TNBC cells and astrocytes promotes brain metastatic colonization.
- siRNA-AuNP targeting of TUBB2B effectively inhibited tumor growth and brain metastasis in preclinical models.
Conclusions:
- TUBB2B is a novel therapeutic target in TNBC.
- Targeting TUBB2B is a promising strategy for inhibiting TNBC cell survival and brain metastasis.
- siRNA-AuNP delivery of TUBB2B-targeting agents shows potential for clinical application in TNBC treatment.
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules

